Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)
Conditions
Interventions
Convalescent anti-SARS-CoV-2 MBT Plasma
Standard Medical Treatment
Locations
12
Spain
Hospital General Universitario de Alicante
Alicante, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitari de Girona Doctor Josep Trueta
Girona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Spain
Fundación Jimenez Diaz
Madrid, Spain
Start Date
April 29, 2020
Primary Completion Date
February 4, 2021
Completion Date
February 4, 2021
Last Updated
March 3, 2021
NCT06082518
NCT07221162
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Instituto Grifols, S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions